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ABSTRACT

The Evaluation of the Use of a Paper Tracking Form to
Improve Provider Adherence to Lipid Guidelines
Diane Ladd, MSN, FNP-BC
Heart disease is the leading cause of death in men and women in the United States. Significant
research into the risk factors for cardiovascular disease has been done, and the effect of
hyperlipidemia on cardiovascular risk has been well documented. Recent research has shown
that there is a lack of adherence to lipid guidelines by primary care providers. Failure to follow
clinical guidelines for lipid disorders leads to increased cardiovascular morbidity and mortality.
The objective of the project was to evaluate whether a simple, paper-based, lipid tracking form
could improve provider adherence to current lipid guidelines. This descriptive study used a prepost test design. Baseline adherence to lipid guidelines was determined by chart review of a
random sample of current practice patients. The lipid-tracking form was placed on the charts of
all patients seen for routine office visits during a specified time frame. After the lipid-tracking
form collection period was completed, a random sample of those patients was reviewed to
reassess adherence to lipid guidelines. The post-implementation date was compared to the
baseline data. The use of the lipid-tracking form did demonstrate an improvement in adherence
to lipid guidelines as demonstrated by an increase in the number of patients who had a
documented LDL goal (p=0.000). In practices without electronic medical records, this simple,
inexpensive, paper-based tool can help providers improve adherence to lipid guidelines.
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Chapter I: Introduction
Heart disease is the leading cause of death for men and women in the United States
(Center for Disease Control and Prevention [CDC], 2009). Coronary heart disease (CHD), the
narrowing of the coronary arteries due to fatty build-up of plaque, caused 425,425 deaths in the
U.S. in 2006 (American Heart association [AHA], 2006). The American Heart Association and
National Heart, Lung, and Blood Institute (NHLBI) estimated that the direct and indirect cost of
cardiovascular disease in the U.S. for 2009 was 475.3 billion dollars (AHA, 2010). Direct costs
include healthcare providers and medications, and indirect costs refer to the loss of productivity
from disability and death. The economic cost can be measured, but the true human cost of
debility, suffering, and death is incalculable.
Background and Significance
Statement of the problem.
Failure to follow clinical guidelines for hyperlipidemia (HLD) screening, treatment, and
follow-up leads to increased cardiovascular morbidity and mortality, which is a significant
healthcare burden in money, time, and disability.
Description of the problem.
Heart disease is the leading cause of death in most ethnic groups in the United States
including African Americans, American Indians or Alaska Natives, Hispanics, and Caucasians,
while for Asians, heart disease is second to cancer (CDC, 2009). The heart disease death rates
per 100,000 persons in the United States are highest in Blacks (662) and second highest in
Caucasians (529) (CDC, 2009). The heart disease death rates in Michigan (per 100,000), where
this project occurred, are highest in ethnic populations. American Indians had the highest heart
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disease death rate (805), and African Americans had the second highest heart disease death rate
(709), while whites had a rate of 561. Midland County Michigan‟s heart disease death rate was
highest in American Indians (759), second highest in African Americans (659), and third highest
in whites (580). Overall Midland‟s heart disease death rate was higher than the United States for
total population (585 v. 536), more than double for American Indian (759 v. 352), more or less
equivalent for African Americans (659 v. 662), higher for Hispanics (409 v. 348) and higher for
whites (580 v. 529) (Figure 1). Sager et al. (2010) calculated that adherence to lipid guidelines
for cholesterol targets would prevent 50-80 heart attacks, strokes, and cardiovascular disease
deaths per 1000 persons over a ten-year period.
The INTERHEART study (Yusuf et al., 2004), a large multi-ethnic case-control study,
that was conducted in 52 countries has shown that there are nine easily measured cardiovascular
risk factors that account for over 90% of the risk of acute myocardial infarction and other
cardiovascular problems (lipids, smoking, hypertension, diabetes, obesity, diet, physical activity,
alcohol consumption, and psychosocial factors). The most significant risk factor is
hyperlipidemia (Yusuf et al., 2004). Hyperlipidemia is the presence of elevated lipid and
lipoprotein levels in the blood. The link between lipid abnormalities especially increased lowdensity lipoprotein (LDL) levels and cardiovascular risk has been well established (Karthikeyan
et al., 2009). LDL is the primary atherogenic lipid particle, and it is directly related to the
development of atherosclerosis (Jones, 2010).
Data from the American Heart Association (2010) shows that approximately 102.2
million adults in the United States have total cholesterol levels over 200 mg/dl. The prevalence
of elevated total cholesterol (> 200 mg/dl) is highest in Hispanics at 51.1%. It is second highest
in whites 45.0%. Of the ethnicities studied, the prevalence of elevated total cholesterol (>200
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mg/dl) was lowest in Blacks at 40.2%. From those about 35.7 million have total cholesterol
levels greater than 240 mg/dl. Utilizing the National Health and Nutrition Examinations Survey
(NHANES) data, the AHA further subdivided the data by ethnicity (Black, Hispanic, and White),
gender, and measures of increased cardiovascular (CV) risk (total cholesterol > 240 mg/dl, LDL
> 130 mg/dl, and HDL < 40 mg/dl). Additional data for total cholesterol >240 mg/dl showed the
prevalence to be highest in Hispanics at 16.8%, followed by Whites at 15.3%, and then Blacks at
10.9%. The prevalence of LDL >130 was found to be highest in Hispanics at 42.7%, second
highest in Blacks 34.4% and lowest in Whites 31.5%. In addition, the AHA also provided
prevalence data for HDL < 40. The highest prevalence was highest in Hispanics at 29.3%,
second in Whites at 25.4%, and lowest in Blacks at 14.7% (Figure 2).
Coronary heart disease is usually caused by atherosclerosis (a buildup of fatty material
and plaque inside the coronary arteries). Atherosclerosis is progressive and begins early in life.
Forensic data from the Pathologic Determinants of Atherosclerosis in Youth (PDAY) study has
shown the presence of fatty streaks in segments of the arterial system of all teenagers autopsied
(McGill & McMahan, 1998). In addition, they found fatty plaques in the aorta and coronary
arteries that increased with age. Despite decades of research on lipids and coronary risk, there is
still controversy over which lipid measurement is the most accurate predictor of cardiovascular
risk. Current guidelines from the National Cholesterol Education Program: Adult Treatment
Panel-III (ATP-III) has identified low-density lipoprotein (LDL) as the primary target for lipidlowering therapy for the reduction cardiovascular risk (Pasternak, 2002).
There is sufficient evidence from clinical trials that identifies an association between a
decrease in cardiovascular morbidity and mortality with the decrease in atherogenic particles
(Jones, 2010). This has been demonstrated in patients with and without pre-existing
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cardiovascular disease (Corrao, Conti, Merlino, Catapano, & Mancia, 2010). Despite the
abundance of evidence demonstrating the benefits of lipid control, there is still a significant
failure of providers to appropriately screen, treat, or assign appropriate goals for lipid
management (Sager et al., 2010). Therefore, the purpose of this project is to evaluate the use of a
paper-based lipid tracking tool on provider adherence to lipid lowering guidelines.
Theoretical Framework
One theory that can be used to guide the implementation of new guidelines, protocols, or
practice changes is Rogers‟ Diffusion of Innovations Theory (Rogers, 1962). This theory is used
to describe how, why, and at what rate innovations are adopted and disseminated. Contributions
from other disciplines impacting this theory include: anthropology, sociology, education, and
industrial and medical sociology (Ryan, 1943). One of basic premises of this theory is that
innovation is adopted slowly during the beginning of the process then, once it is perceived to be
beneficial, it is adopted more quickly. There are distinct elements in the Diffusion of Innovations
Theory. They include: types of communication, time, rate of adoption, and the type of system or
group for which the innovation is intended. For this capstone project, the site specific needs and
deficiencies were taken into consideration. Communication regarding the project was in written
form, as well as verbal, to provide concrete information and references for the staff. The type of
system (small private practice) was taken into consideration in the project design.
Rogers‟ Diffusion of Innovations Theory is a five-step process. The five steps are: (1)
knowledge; (2) persuasion; (3) decision; (4) implementation; and 5) confirmation (Figure 3).
The knowledge step involves gaining and recalling knowledge about the innovation. The
persuasion step is when an individual becomes interested in the innovation, shares with others
the positive role of the innovation within the group, and gathers support for the innovation within
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the system. During the decision making step, additional information is gathered and the
innovation is initially adopted or rejected. The implementation step is when the innovation is
utilized on a routine basis, and its usefulness and barriers can be determined. The fifth step of
confirmation is when the group recognizes the benefits and integrates the innovation into the
systems ongoing routine (Sharma & Kanekar, 2008; Martin, 2009). This investigator has
identified other steps that may be necessary when implementing guidelines, protocols, or practice
changes. Rogers (1962) proposed that in the decision step the innovation will either be adopted
or rejected. This investigator proposed that rather than outright rejection, the next step, if the
innovation is not adopted, would be initial rejection. After initial rejection, there should be a
reevaluation of the proposed innovation to assess its lack of adoptability. If it is determined that
the innovation is still appropriate to the system, and should be adopted, then it should be reintroduced to the system beginning at the knowledge step. However, if it is determined that the
innovation is not appropriate for the system, the last step would be final rejection. Once an
innovation has gotten to the final rejection step, it should not be reintroduced back into the same
system without changes (Figure 4).
Another significant factor in the use of this theory is identifying the rate of adoption.
Each innovation is adopted at a different rate, and the speed at which the new innovation is
adopted is determined, in part, by the adopter categories. Rogers (1962) describes five adopter
categories: innovators, early adopters, early majority, late majority, and laggards. Innovators are
usually the first to adopt an intervention. They are usually risk takers and tend to be younger in
age. Early adopters are the second fastest category of adopters. They tend to have a high degree
of leadership. The early majority are individuals who adopt after varying lengths of exposure to
the innovation. These adopters take longer than the first two groups and tend to be slower in
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adopting. The late majority adopts the innovation only after other members of the group have
adopted it. The late majority tend to be skeptical and wait to see what others have done. The
laggards are the last to adopt an innovation and are generally averse to change. The breakdown
of these categories forms a normal distribution curve (Figure 5).
In addition to the adopter categories, Rogers (1962) has described factors that influence
the rate of adoption. These include: relative advantage, compatibility, complexity,
trialability/testability, and observability. The relative advantage is the perceived advantage of
the innovation within the group or system. Compatibility refers to the amount of compatibility
the proposed innovation has within the already existing system or structure as well as values and
needs of the adopters. Complexity involves not only the amount of work required to incorporate
innovation within the group or system but also the perceived barriers to adopting the innovation.
Trialability/testability refers to the amount to which an innovation can be tried on a limited basis.
Observability is the amount to which the results of the innovation are visible to others. It is
easier for people to adopt and accept an innovation if they can easily see the results (Decivita &
Dasgupta, 2007). The lipid-tracking tool provides an at-a-glance record that shows the progress
(or lack thereof) of the patient lipid control and increases the observability of the innovation
(practice change). In addition, the at-a-glance style of the form will reinforce the relative
advantage (not having to look through the chart for history and lipid trends) of the innovation.
The innovation is not complex, and there are no significant barriers such as need for specialized
knowledge or technology.
This theory was useful in implementing structured screening, treatment, and follow-up
protocols and practice changes for the evaluation and treatment of hyperlipidemia. The first
stage is the stage of knowledge attainment. During this stage, knowledge of the new guidelines
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and the rationale for change was communicated to all members of the health care team. It is
important to stress that these guidelines were developed after many years of research and review.
Opportunities for team members to ask questions and express concerns were provided. Once the
information and rationale on the new guidelines had been given to the team members, it was
important to identify those who were actively seeking more information regarding the
implementation and guidelines. The innovators and early adopters were utilized to help
incorporate the innovation into clinical practice.
The second stage was the persuasion stage. Employees who showed interest in the
guidelines and interventions and were proactive in seeking information and providing solutions
were utilized to assist in bringing others on board and spearheading group-wide changes. In
addition, during this stage, barriers and problems related to the innovation were identified and
addressed. It was beneficial to use the innovators and early adopters to help develop specific
processes for implementation of the guidelines.
In the third stage, the decision-making process, the initial decision to incorporate any
changes was made. During this process, it was easy to identify those who have not yet adopted
the new guidelines or who were resistant to change. If there were a significant number of nonadopters in the group, it might have been prudent to delay the implementation of the guidelines
and redirect efforts into the knowledge and persuasion stages. When the decision to implement
the new guidelines was made, then formal planning began. In order to plan a significant practice
change, all team members needed to fully understand the processes involved. This included
development of new tools and restructuring of processes. During this stage, additional barriers
and problems were identified and solutions sought. The intermediate stage of initial rejection led
to a reevaluation of the innovation (practice change) and the system. If the innovation fails to be
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adopted, then it would be at the initial rejection phase, and the reevaluation will would allow the
innovation to be assessed and reintroduced at the beginning, knowledge step, to improve the
chance that it would be adopted. The innovators and the early adopters can be utilized for the
reevaluation and re-introduction.
Stage four is the implementation phase. During this stage, members of the group worked
together to implement the guidelines and processes. The goal was that a majority of the team
members would adopt the new guidelines. It has been predicted that if 50% of the group support
an innovation, it has a greater than 80% chance of successful implementation (Agyeman et al.,
2009). Stage five, the confirmation stage, was when the change or guidelines and processes
would be formally adopted. At this time, the new guidelines and protocols would be put into
routine clinical use. It is important to recognize that even though the intervention or change
might now be part of routine practice, it still needs to be evaluated for effectiveness.
While the Diffusion of Innovations theory is a good model for introducing clinical
guidelines or practice changes, it does not come without problems. The implementation of a new
guideline, process, or practice change is not a fast process, and that needs to be effectively
communicated. The initial adoption is a slow process that speeds up as more members of the
system agree with the innovation or change. Expectations of a quick adoption process and
implementation can lead to problems, disillusion, and ultimately failure to implement the
innovation. Interventions that are preventative in nature are harder to adopt because there is no
immediate measurable benefit.
The usefulness of this theory has been demonstrated in the corporate, athletic, and
practice settings. One of the best resources for the use of this theory is to identify and involve
innovators who are excited about practice change, have appropriate levels of knowledge, and are
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considered leaders within the group. One of the barriers to the use of this theory in the clinical
practice setting may be a culture of resistance to change. Another barrier could be the general
lack of knowledge and understanding regarding the generation of new guidelines and their role in
prevention. One of the best ways to assist in implementing any practice change especially in the
clinical practice setting is to recognize that change occurs slowly and to begin efforts early in
anticipation of a needed practice change.
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Chapter II: Review of the Literature
Search Strategy
The articles for review were identified by searching electronic databases. The databases
searched were: the Cochrane Library, Academic Search Complete, CINAHL, and Medline. The
keywords used were: adherence, guidelines, and lipids. No systematic reviews were identified
from the search. The initial search yielded 319 results. The results were narrowed to include
only articles published within the last five years, human studies, articles published in peerreviewed journals, and available in English. Seven studies were selected for the review based on
the strength of evidence and relevance to the problem. The seven studies included: one
randomized controlled trial (Hung, Lin, Hwang, Tsai, & Li, 2010), and six cross-sectional
surveys (Barham et al., 2009; Gowani et al., 2009; Laforest et al., 2008; Lewis, Robinson, Fox,
& Grandy, 2010; Sager et al., 2010; Vulic, Lee, Dede, Lopez, & Wong, 2010).
Literature Review
The randomized controlled trial (RCT) evaluated the use of a paper chart reminder on
guideline adherence in lipid management in Taiwan (Hung et al., 2010). The study randomized
patients with angiographically proven CHD who were not on lipid-lowering therapy (LLT) into
either the control group or the intervention group. The intervention was a paper reminder that
was placed on the chart that stated “Statins can be beneficial to patients with documented
coronary artery disease regardless of their LDL level.” Below that statement was the detailed
reimbursement policy for the National Health Insurance of Taiwan. If no action was taken after
three months, a second reminder was placed on the charts. The study had two end points; the
primary endpoint was a new prescription for LLT (statin or ezetimibe) during the six month
follow-up period, the secondary endpoint was the composite of LLT or repeat lipid profile within
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six months. The investigators randomized 194 patients, 92 to the study group and 102 to the
control group. The groups were well-matched. The inclusion and exclusion criteria were well
described. There were new LLT prescriptions in 14.1% of the study group and 8.8% of the
control group. The odds-ratio (OR) for LLT was 1.70 (P=0.248, 95% CI: 0.69-4.19). The
secondary endpoint showed better results in the study group. The study group had repeat lipid
panels in 59.8% of the patients. The control group only had 35.3% of patients with repeat lipid
panels. The OR for the secondary endpoint was 2.81 (P=0.001, 95% CI: 1.57-5.04). The
investigators were unable to see a significant improvement in the primary endpoint, but did see
an improvement in the secondary endpoint. The inclusion of the reimbursement policy on the
reminder is thought to be a significant factor in the lack of improvement in the primary endpoint.
The reimbursement policy (which does not reimburse unless LDL ≥ 130) contradicts the other
statement that the use of a statin is beneficial regardless of LDL level. The studies strength is its
RCT design. Its weaknesses are: the small sample size, lack of ethnic diversity, and policy
restrictions that affected the primary endpoint.
There were six cross-sectional surveys (CSS) reviewed. The first CSS evaluated the
appropriateness of cholesterol management in primary care. The investigators (Barham et al.,
2009) evaluated the appropriateness of cholesterol management in relation to cardiovascular risk
and sex. They examined medical records from 60 community practices in North Carolina that
were participating in a randomized practice-based trail (Guideline Adherence for Heart Health).
They investigated 5031 patients aged 21-84 years. The investigators used a multivariate logistic
regression to assess whether age, sex, race, diabetes, cardiovascular disease, ATP-III risk
category, or pre-treatment LDL influenced treatment for lipid disorders. They found that
screening rates were higher in those who were older and those who had diabetes or
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cardiovascular disease. However, they did not see any large difference in screening rates by sex.
They found that older age was associated with less appropriate lipid treatment (OR 0.91, P=0.01)
even though older adults had higher screening rates. In addition, they found that patients with
LDL ≤ 130 and those in the low cardiovascular risk category were more likely to be managed
appropriately when compared with those whose LDL ≥ 190 and those at high risk (OR 18.8, P <
0.001; OR 27.5, P <0.001). Investigators also found that of the 375 patients eligible for
treatment, those with LDL levels ≥ 131 and ≤ 159 were less likely to be treated compared to
those with LDL ≥ 190 (OR 0.15, P=<0.001). They concluded that adherence to ATP-III
guidelines is more challenging in intermediate-risk and high-risk patients than for those at lowrisk, and patients in those categories were significantly less likely to be managed appropriately.
This study‟s strength is its large sample size and use of multiple practices. It weaknesses are in
the CSS design and the data (medical record) abstraction, which may not have captured all of the
actual patient data.
Another cross-sectional survey evaluated LDL goal attainment in patients receiving LLT
(LaForest et al., 2008). The investigators analyzed 2727 patients obtained from a French
computerized general practice database. The patients were selected from randomly chosen
providers in the database. They included patients who had a diagnosis of dyslipidemia
(hyperlipidemia) and had a visit within the selected time frame. In addition, the patient had to be
treated with at least one lipid-lowering agent (LLA). The investigators examined the number of
patients who reached therapeutic objective (TO). They found that only 58.5% of the high-risk
patients met the TO for the overall analysis. When the data was analyzed based specifically on
cardiovascular risk, the investigators found that significant differences were observed especially
at the high risk level. They found that only 42% of high risk patients met the TO (P < 0.0001).
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In addition, they also found that when patients had a history of CVD and diabetes, there was a
higher percentage (57%) of patients that had reached TO compared to patients with only CVD
(42%), and those who were without CVD but at high risk (32%) and being treated as primary
prevention (P< 0.0001). The strengths of this study are its large sample size and the use of
random selection of practices from which to collect data, as well as the large number of practices
sampled. Its weaknesses are using guidelines other than ATP-III, although they are similar, and
the use of multiple risk categories and sub-categories.
The third cross-sectional survey examined the underutilization of cardiovascular
medications in at risk individuals (Lewis, Robinson, Fox, & Grandy, 2010). The investigators
identified patients from the SHEILD (Study to Help Improve Early evaluation and management
of risk factors Leading to Diabetes) study who were at risk for or with a history of CVD events
such as MI, stroke, or revascularization. CHD risk was defined using the ATP-III guidelines.
The respondents were divided into three categories: high CHD risk (7510), moderate CHD risk
(4823), and low CHD risk (5307). The investigators found that the use of LLT was very low in
each group (21.5%, 13.0%, 5.5% respectively; p < 0.001). After adjusting for age, gender, and
geography, they found that high and moderate CHD risk groups were more likely to have gotten
LLT than the low-risk participants (p < 0.001). The high-risk group was over four times more
likely to have had statin therapy (OR 4.60, 95% CI: 3.54-5.97) and the moderate-risk group was
over three times more likely (OR 3.13, 95% CI: 2.45-3.99) to have statin therapy than the lowrisk group. In addition, they found that within the high-risk group, participants with a history of
prior CVD event got LLT more often (25%) than those with type II diabetes (19.5%; p=0.02).
The investigators also found that participants who had type II diabetes were receiving LLT more
often than those in the moderate and low risk groups (p < 0.001). This study‟s strength is its
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large sample size and use of established guidelines for quantifying risk (ATP-III). Its weaknesses
are its use of self-report data and its examination of only the use of LLT and not the management
of HLD.
Another cross-sectional survey assessed adherence to published lipid treatment guidelines
among cardiologists in Pakistan (Gowani et al., 2009). The investigators developed a structured
questionnaire to collect information regarding: fundamental knowledge of the basic practices in
lipid management, evidence of sex or age bias, and demographics including continuing medical
education (CME) activities. The questionnaire was piloted with ten cardiologists who were not
part of the study. Feedback from the pilot study provided information to the investigators, the
questionnaire was shortened, and some of the language was changed to clarify some of the
questions. The study participants were 239 cardiologists from multiple centers in Pakistan who
completed a questionnaire. The questionnaire had a maximum score of 14. In addition, data on
the cardiologists‟ education, type of cardiology practiced, and exposure to continuing medical
education (CME) was collected. The median score on the questionnaire was nine. The
investigators found that there were fewer correct answers from the cardiologists in areas dealing
with fundamental issues such as: initial choice of therapy (77.0 %); the maintenance of
therapeutic dose after goal is attained (46.9%); and lack of aggressive treatment of LDL (16.7%).
In addition, they demonstrated that the cardiologists indicated that there was bias regarding
patient age in respect to different LDL goals (41.8%) and different thresholds for starting therapy
(35.1%). They also identified physician bias towards patients of different sexes. They noted that
there were reported differences in thresholds for starting therapy in women (43.5%) and different
LDL targets in women (46.4%). They found that 73% of the cardiologists who reported a bias
were less aggressive in treating women. In the adjusted analysis, it was noted that years of

IMPROVING PROVIDER ADHERENCE TO LIPID GUIDELINES

15

experience, practice in interventional cardiology, and exposure to CME was associated with
increased knowledge (P=0.005; P=0.041; P=0.001, respectively). The study‟s strengths are the
use of a pilot study prior to implementation as well as the use of well recognized lipid guidelines
(ATP-III). The weaknesses are: absence of reliability and validity information on the
questionnaire, lack of ethnic diversity, and a lack of regulation of medical specialty practice in
Pakistan however, that was addressed somewhat by the study design.
The fifth cross-sectional survey evaluated the extent of adherence to recommended
cardiovascular therapies (Vulic et al., 2010). The investigators used a multi-ethnic sample with
CHD. They assessed adherence to recommended therapies for CHD in representative sample of
364 adults with CHD selected from the National Health and Nutrition Examination Survey
(NHANES) database. They calculated the proportion of patients who were receiving
recommended therapy. The investigators found the treatment rates for LLT were lower in
Hispanics (27%) and non Hispanic Blacks (42%) than in non-Hispanic Whites (p < 0.01). In
addition, they also found that lipid-lowering treatment rates were lower in females (50%) as
compared to males (67%) (p < 0.01). The study‟s strengths are its use of the NHANES database
and use of a multi-ethnic sample. Its weaknesses are the small sample size and lack of laboratory
data.
The final cross-sectional study reviewed physicians‟ perception of LDL goals based on
guideline recommendations (Sager et al., 2010). The investigators asked 907 physicians to
determine the LDL goal for 30 of their patients with HLD based on current guidelines (ATP-III).
They divided the 25,250 patients into three different LDL target groups (< 100, < 130, and <
160). The investigators used a logistic regression to evaluate whether the physicians‟
incorporated risk factors and comorbidities correctly to determine the proper LDL target. They
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found that the physicians identified the correct LDL target in only 55.1% of male patients versus
49.1% of females (P < 0.001). The data showed that in the group with LDL target < 100, the
correct assignment was most often assigned to male patients with a history of CAD and
myocardial infarction (77.1%). The investigators found the correct LDL goal of < 100 in
patients with CAD and concomitant disease. The found the rates to be: CAD and CABG
(76.6%), CAD and diabetes (69.6%), CAD without CABG (61.3%), CAD without diabetes (61.2
%), and CAD without MI (58.4%). They also found in all patients with CAD, that the correct
LDL goal was assigned more often in men than in women (67.6% v. 59.7%; p<0.001). The data
was placed in quartiles based on guideline knowledge. They found that the patients of the
physicians in the top quartile (>90% correct LDL goals) had lower LDL levels than those in the
other quartiles (p < 0.001). The strength of this study is its large sample size. Its only significant
weakness is the cross-sectional survey design.
Synthesis
The RCT (Hung et al., 2010) showed that the use of a paper-based clinical reminder
could modify provider behavior in assessing lipid values. Unfortunately, this study did not show
an increase in the use of LLT. The inclusion of the reimbursement policy for LLT on the
reminder form significantly affected the use of LLT in the participants, which was the primary
outcome. The reimbursement policy contradicted the other statement that “statins can be
beneficial regardless of LDL level”. It is probable that the absence of the reimbursement policy
statement would have led to a better outcome in terms of better use of LLT. While the study did
not meet its primary outcome, it did adequately demonstrate that the use of a paper-based clinical
reminder could modify provider behavior.
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The six cross sectional surveys clearly demonstrated that there is a lack of provider
adherence to lipid guidelines. The studies addressed different aspects of adherence to lipidlowering guidelines. Two of the studies (Barham et al., 2009; Laforest et al., 2008) examined
lipid management and found that those at high risk were less likely to receive appropriate
treatments or reach therapeutic objective (goal). Two of the studies reviewed treatment rates (for
LLT) and utilization of LLT (Lewis et al., 2010; Vulic et al., 2010). Those studies showed that
the treatment rates were low for all groups studied. Two of the studies (Gowami, et al., 2009;
Sager et al., 2010) evaluated provider knowledge and adherence to lipid-lowering guidelines and
demonstrated that there was a distinct lack of provider knowledge as well as a failure to identify
correct LDL targets. In addition, three of the studies (Gowani et al., 2009; Sager et al., 2010;
Vulic et al., 2010) showed that providers were more likely to treat and manage lipids more
aggressively in men than in women. Two studies (Barham et al., 2009; Vulic et al., 2010)
demonstrated that there was age bias as older age was associated with less appropriate treatment.
Also, one study found that there was a lack of adequate treatment in some ethnicities especially
Hispanics and non-Hispanic Blacks (Vulic et al., 2010). Four of the studies had large sample
sizes (Barham et al., 2009; Laforest et al., 2008; Lewis, et al., 2010; Sager et al., 2010). All four
of these studies clearly showed that there is a lack of provider adherence to lipid guidelines. This
is especially noted in those patients in the high risk categories in all three of these studies
(Barham et al., 2009; Laforest et al., 2008; Lewis, et al., 2010). Other cross-sectional studies
(Gowani et al., 2009; Vulic et al., 2010) with smaller sample sizes also showed that there was a
lack of provider adherence to lipid-lowering guidelines.
Overall the body of evidence from the cross-sectional surveys clearly demonstrates that
not only is there a lack of provider adherence to lipid guidelines, but that those at high risk, some
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minorities, and women are especially vulnerable to undertreatment. There were no significant
knowledge gaps identified. The RCT adequately showed that the use of a paper-based clinical
reminder modified provider behavior. The hypothesis for the project is that: the use of a simple
paper lipid-tracking tool in a primary care practice (without EMR) will improve provider
adherence to lipid-lowering guidelines and improve patient care. The objective of the RCT is
well matched to the hypothesis of the capstone proposal, that a paper based intervention can
modify provider behavior. The body of evidence substantiates the need for protocol change that
includes a paper based clinical reminder to help modify provider behavior and improve provider
adherence to clinical guidelines (ATP-III) for lipid disorders.
Congruence of Organizations Strategic Plan to the Capstone Project
The goal of the practice is to provide high quality, efficient, ongoing comprehensive
medical care for the patients it serves. A large number of the patients have chronic medical
conditions such as diabetes, hypertension, chronic kidney disease, and hyperlipidemia. The
primary goal of the project is to improve provider adherence to clinical guidelines for lipid
disorders. This is in line with the overall goals of the practice.
Project Objectives
The hypothesis for the project is that the use of a simple paper lipid-tracking tool in a
primary care practice (without EMR) will improve provider adherence to lipid-lowering
guidelines and improve patient care. The specific objectives for the project after the protocol
change are: (1) to educate the staff regarding lipid guidelines through the use of the lipidtracking form (LTF) and lipid guidelines; (2) to assess the baseline adherence to lipid guideline
from chart review using the data collection form (DCF) and data prior to the intervention; (3) to
demonstrate an increase in screening for lipid disorders after the intervention; (4) to identify
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from the chart review after the protocol change an improvement in the number of patients with
abnormal lipid values who are correctly diagnosed with hyperlipidemia (HLD); (5) to increase in
the number of patients that have an identified LDL goal after the protocol change; (6) to increase
the number of patients who have the correct LDL goal identified; (7) to identify an improvement
in the number of patients who are given the correct medications for HLD; (8) to increase in the
number of patients who are getting correct follow-up for lipid disorders. It is anticipated that
these changes will be both statistically and clinically significant.
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Chapter III: Methodology
Project Design
This capstone project used a descriptive, retrospective, before and after design. The
project was designed to evaluate the use of a simple paper tracking form on provider adherence
to lipid guidelines (ATP-III). There was a pre and post intervention analysis and specific
objective measurements of lipid guideline adherence were compared. There was an analysis of a
random sample of patients to determine baseline adherence to lipid guidelines prior to the
intervention. These patients were randomly selected from the practice database. During a
specific time frame, twenty-three consecutive days, the tracking form was placed on the charts of
all patients coming to the office for routine office visits. Patients coming to the office for joint
injections or dermatological procedures were excluded. The practice is relatively small,
approximately 1500 active patients, with only three providers including the project leader. All
patients seen during the evaluation period received the intervention (lipid-tracking form)
including those seen by the project leader, but that data was removed prior to analysis in order to
eliminate bias. After the intervention period, the lipid tracking forms were collected and
analyzed. A random sample of the lipid tracking forms were analyzed for comparison to the
baseline data.
Resources
This project did not require many resources other than the project leader‟s time. Office
supplies such as paper, ink, and photocopying were provided by the site. Educational materials
were already present at the site and provided by an outside vendor (non-pharmaceutical). The
data collection form and lipid tracking tool were developed and printed by the project leader.
There is little or no need for additional involvement of ancillary staff as any work involved in the
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project (making labs slips, scheduling appointments) was already part of their current work
duties, and were not in excess. The other providers in the practice were asked to complete the
form at the time of the patient visit. This did not significantly impact the time needed for each
patient visit. It took less than two minutes to complete the lipid tracking form. Each provider
did have a face-to-face in-service on the use of the form as well as written instructions
(Appendix A).
The data collection form (DCF) was intended to collect specific objective data on
measures of guideline adherence. This form was used to collect the pre and post intervention
data. In addition, the form was used to collect baseline demographic data. The data collected
included: project identifier (no names were used), date of birth, age, date of last clinic visit,
comorbidities (diabetes, coronary artery disease, peripheral vascular disease, stroke), family
history of heart disease, date of last lipid profile, diagnosis of HLD, medications for HDL, date
of follow-up lipid panel, LDL target, correct LDL target, and whether the patient was at or below
LDL target (Appendix B). These data tracking forms were completed by the project leader and
were not intended for use by the other providers.
The lipid-tracking form (LTF) was intended it improve provider adherence to lipid
guidelines by providing the needed information in one easily accessible place. The form
consisted of a grid that provided information on the patients‟ lipid values, medications,
medication changes, planned follow-up, and comments (e.g. missed doses, side effects). The top
part of the form included areas for information about the patients‟ comorbidities (CVD risk), and
their LDL goal (Appendix C). In addition, a portion of the ATP-III guidelines (Appendix D)
were printed on the form. Also included on the form is the recommended follow-up. This form
was intended to be completed by the provider at the time of the patient visit.
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Evidence of Key Site Support
The site for the implementation of the capstone project was a small independent Internal
Medicine practice in Midland County, Michigan. The practice owner was supportive of the
project leader‟s participation in the DNP program. There were multiple discussions between the
practice owner and the project leader regarding the project and how it would fit in with the
practice. A signed letter allowing the project to be performed at the site was obtained (Appendix
E).
Procedure
The implementation of the practice change occurred in several steps. Prior to
implementing the practice change, multiple discussions were held with the other providers in the
practice to review the lipid tracking form (LFT) and obtain input on the format. The feedback
was utilized in the development of the final form (Appendix C). The providers were given a
copy of the ATP-III quick reference guide and the Framingham risk charts (Appendices D & F).
In addition, copies of these were placed in all of the exam rooms. Instructions for the use of the
lipid tracking form were given to each provider (Appendix A). Verbal instructions were also
provided. The project was submitted the West Virginia University Institutional Review Board
(IRB) for review. It was reviewed by the IRB and determined to be exempt.
The evaluation period consisted of 23 consecutive business days. The lipid tracking
forms were placed on the charts of the eligible patients by the project leader. This was done just
before the patient visit, either the evening before or morning of the visit. The project leader
filled out preliminary information on the lipid tracking forms. This included: age, gender, and
the most recent lipid values. The providers were expected to fill out the data on comorbidities,
determine and document the LDL goal, and indicate medications and follow-up. During the
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evaluation period there were 336 forms placed on the charts. Of the eligible charts, the forms
were placed on 100% of the charts. The forms were left on the charts during the entire
evaluation period. After the evaluation period the forms were retrieved. Of the 336 forms that
were deployed, 333 were retrieved (99.1%). Since the forms were placed on the charts just prior
to the patient visits, some forms were not eligible to be completed because the patient did not
make their appointment. Of the 333 forms that were collected 20 of those where on charts where
the patient did not make their visit leaving 313 forms. The sample was then further reduced by
excluding the patients that were seen by the project leader yielding a 233 post practice change
sample. From this sample 100 forms were randomly selected for analysis. Excluding the project
leader only one of the two providers who participated in the evaluation of the practice change
completed any of the forms. That provider completed approximately 45% of the eligible forms.
Evaluation
The evaluation of the project had several components. The first component was the
evaluation of baseline adherence to lipid guidelines. This involved the collection of data on 100
randomly selected patient charts on the data collection form (Appendix B) to track objective
markers of adherence (screening, diagnosis, treatment, follow-up, identified LDL goal, and
treatment to goal). The second component examined two factors in the implementation of the
practice change. The percentage of patients who received the lipid-tracking form was
determined. This was accomplished by calculating the number of patients seen during the
specified time frame and dividing that into the total number of patients who actually received the
lipid-tracking form during that time. This was calculated to be >99%. In addition, provider
compliance with the project was also calculated. This was done by determining the number of
patients who received the lipid tracking form and dividing that into the number of completed
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lipid tracking forms. This was also broken down by provider. This was expected to be > 75%.
This was to measure implementation of the practice change not patient adherence. The third
component was the determination of post-intervention adherence to lipid guidelines. A random
sample of the patient‟s lipid tracking forms were reviewed using the data collection tool and
compared to the random patient sample that was analyzed prior to the intervention to determine
if the lipid tracking tool improved provider adherence to lipid guidelines. This evaluated specific
areas of adherence. In order to compare the results of two groups a chi-square test and
independent t-test were used. A p value of < 0.05 was set for statistical significance.
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Chapter IV: Results
Sample Characteristics
There are two samples that will be described in the remainder of this paper: (1) the
baseline sample and; (2) the post practice-change sample. The baseline sample (BLS) was a
sample consisting of 100 randomly selected charts from the practice cohort. This sample
consisted of patients over the age of 20 who did not have the project leader as a primary care
provider. The post practice-change sample (PPS) consists of a random selection of 100 patients
who received the practice change (LTF). It consisted of patients who were seen by the other
providers in the practice. The patients who were seen by the project leader were excluded from
selection. The baseline sample (n=100) had a mean age of 67.73 years with a standard deviation
of 14.098 years. The minimum age was 37 years and the maximum age was 94 years. The postpractice change sample (n=100) had a mean age of 69.66 years with a standard deviation of
12.173 years. The minimum age was 41 years and the maximum age was 93 years. An
independent t-test confirmed that there was no statistically significant difference in the ages of
the two samples (p=0.301). The gender distributions in both the pre and post samples were also
compared. The baseline sample was 47% male and 53% female. In the post practice-change
sample was 51% male and 49% female. A chi-square test showed there was not a statistically
significant difference in gender in the samples (p=0.572). Race/ethnicity was not analyzed
because the baseline characteristic of the practice cohort is predominantly Caucasian (98.66%).
This is consistent with the racial breakdown in Midland County (96.25%).
Assessment of Baseline Adherence
To determine baseline adherence to lipid guidelines the baseline sample of patients from
the practice cohort were reviewed. Specific criteria were tracked using the data collection form
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(DCF). The criteria were chosen to address the project objectives. The objectives that were
addressed in the analysis of baseline adherence included: (1) evaluation of patients who had
proper screening; (2) determination of patients who had the correct diagnosis of hyperlipidemia;
(3) the number of patients who had a documented LDL goal; (4) the number of patients who had
the correct LDL goal; (5) evaluation of the use of correct medication to treat hyperlipidemia; and
(6) evaluation of the number of patients who had appropriate follow-up. The assessment was
done on data that preceded the practice change. The data collected included: date of visit, date of
the most recent labs that preceded the visit, specific comorbidities (diabetes, coronary artery
disease, and evidence of need for secondary prevention), lipid values, evidence of LLT, and
follow-up.
Screening.
To determine adherence to screening recommendations, the time between the lab date
and the visit date were calculated (lab-days). In addition, follow-up lipid testing was also
considered. Based on the calculation of lab-days, it was determined that adequate adherence to
lipid screening was achieved at baseline. The mean number of lab-days (number of days
between labs and visit) prior to the practice change was 129.77 days, the minimum number of
days was 0 and the maximum was 1555. Recommended screening for patients with chronic
disease is annually (364 days) and the recommended screening for those without chronic disease
is at least every 5 years (1820 days). An independent t-test showed that there was no association
between lab-days and patients who were not at or below goal (p=0.533).
Assessment of diagnosis of hyperlipidemia.
The baseline sample was reviewed for patients with abnormal lipid values who did not
have evidence of either a diagnosis of hyperlipidemia, (hyperlipidemia, dyslipidemia, or
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hypercholesteremia) or evidence of treatment with lipid lowering therapy. There were not a
significant number of patients who had abnormal lipid values who did not have a documented
diagnosis or evidence of treatment with lipid lowering therapy. However the absence of
documented LDL goals makes this difficult to ascertain. The diagnosis of HLD is relative to the
goal. The project leader established estimated goals based on the evidence available for review.
Based on the estimated goals there were six patients identified that did not have a diagnosis of
HLD (either documented or evidence of LLT) and who were not at or below the goal. A chisquare test showed that this was not statistically significant (p=0.790). At the competition of the
project these patient charts were referred to the provider for further review.
Documentation of LDL goal.
In the baseline sample there we no documented LDL goals in the charts reviewed.
Because there were no documented LDL goals, there was not an opportunity to evaluate whether
or not they were the appropriate goals. However, the project leader estimated the LDL goals,
based on the information that was available for review in the chart, to determine whether or not
the patients were at or below goal. Based on estimated goals determined by the project leader, it
was found the 28% of the sample was not at or below goal, and that 72% of the patients were at
or below the estimated goal.
Assessment of medication usage to treat hyperlipidemia.
The baseline sample was also analyzed to review the use of medications in the treatment
of hyperlipidemia. In addition to the chart review, the electronic prescription system was also
reviewed. It was difficult to assess due to individual provider preferences for the use of different
medications in the treatment of lipid disorders. In addition, there was lack of adequate
documentation regarding the medication choices, especially in those patients not treated with
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statin therapy. While there are appropriate rationales for the use of non-statin therapy, it is useful
to have documentation on the reasoning behind the choice of non-statin therapy. The data
collection for this project grouped lipid-lowering therapy into four basic categories: 1) statin
therapy, 2) Zetia only, 3) over-the-counter (including fish oil, red yeast rice, etc.), and 4) other
(Welchol, Lovaza, etc.). In the baseline, sample fifty-seven patients had documented therapy
with statins, four were on Zetia alone, five were on over the counter therapies, and five were on
other medications. Comparison with the „at or below goal‟ (estimated) measure using a chisquare test showed that there were at total of eight patients who were not receiving any treatment
who were not at or below goal. This was not statistically significant (p=0.814).
Follow-up.
Another indicator of adherence to lipid guidelines that was evaluated is the appropriate
follow-up for patients with lipid disorders. This includes visits and labs. The baseline sample
was used to determine baseline adherence to follow-up. The determination of follow-up was
calculated using chart review and the follow-up guidelines for patients with hyperlipidemia.
These follow-up guidelines were also printed on the lipid tracking form. The follow-up
guidelines were developed in collaboration with the practice owner. The recommended followup was: (1) new diagnosis, change in medication or unstable, six to twelve weeks; (2) if stable
and at goal, three to six months; and (3) patients with chronic disease, annual screening. The
project leader reviewed each chart of the patients in the baseline sample. The measure „followup‟ used a discrete variable of yes/no. Yes to indicate that there was appropriate follow-up
ordered, and no to indicate absence of documented appropriate follow-up. This looked
specifically at provider actions (whether or not follow-up was ordered) not at patient compliance
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with the orders. In the baseline sample there were 22 patients who did not have appropriate
follow-up and 78 who did.
Evaluation of Post Practice-Change Adherence
The post practice change adherence to lipid guidelines was evaluated by comparing
specific criteria from the baseline sample and the post practice change sample. The specific
criteria compared included: 1) documentation of an LDL goal, and 2) appropriate follow-up for
lipids. Age and gender were also compared in the two samples to determine if the samples were
equitable. The samples were determined to have similar distributions of age and gender; the
details are described further in the sample characteristics section.
Documentation of an LDL goal.
One of the project objectives was to increase the number of patients who had a
documented LDL goal. While the response was not as great as the investigator had originally
anticipated, there was an increase in the number of patients who had documented LDL goals,
which was statistically significant. Overall there was a 26% increase in the documentation of an
LDL goal. A chi-square test showed that this was statistically significant (p=0.000). Because
only one provider completed the forms, that provider was solely responsible for the 26%
increase. The appropriateness of these documented goals was reviewed based on the information
that was readily available in the chart. It was observed that some of the LDL goals were more
aggressive than those recommended based on the ATP-III guidelines. This was specifically
noted in patients with diabetes. This was not considered an incorrect goal, because other
guidelines recommend aggressive lipid lowering in patient with diabetes. Analysis using the
more aggressive LDL goals did not indicate and significant difference in the number of patients
who were at or below goal.
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Follow-up.
The post practice change sample was compared to the baseline sample to determine if
there was an increase in the number of patients who were given appropriate follow-up for lipid
disorders. There was an increase in the number of patients with the proper follow-up ordered
after the practice change (82 v. 77) but it was not statistically significant (p=0.457). There was a
corresponding decrease in the number of patients who did not have follow-up ordered. Twentytwo patients in the baseline sample and eighteen in the post practice change sample.
Other Analyses
Because only a single provider (other than the project leader) completed the lipid tracking
forms during the evaluation period, additional analyses were done using the available data to
ascertain if there any other differences between the providers. Lipid data from the combined
data set (baseline and post practice change samples) was analyzed with an independent t-test to
compare the two providers. There were differences noted between the providers in all lipid
values measured (cholesterol, triglycerides, HDL, VLDL, LDL and non-HDL). Provider One
who completed the forms during the evaluation period had patients with lower mean levels of
cholesterol, triglycerides, VLDL, LDL, and non-HDL than Provider Two. Of those, there were
statistically significant differences in cholesterol (p=0.000), LDL (p=0.009), and non-HDL
(p=0.013). These are three of the most significant lipid factors in cardiovascular risk.
In addition, the combined data set was used to evaluate any differences in providers for
follow-up, „at or below goal‟, and use of statin medications. Chi-square analyses were
performed. Comparison between Provider One and Provider Two for appropriate follow-up
showed that there was a statistically significant difference between the two providers (p=0.002).
Provider One had more patients who had appropriate follow-up. Even though Provider Two had
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a higher percentage of patients who were not at or below goal (25.3% v. 23.1%) chi-square
analysis showed that there was no statistical difference between the two providers (p=0.727). In
addition, the two providers were compared on the use of statin medication for the treatment of
HLD. There was no difference noted between the two providers in the use of statin medications
(p=0.235).
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Chapter V: Summary, Discussion & Implications
Congruence with the Theoretical Framework
This capstone project demonstrated congruence with the theoretical framework. Rogers‟
Diffusion of Innovation Theory allows for the possibility that the innovation (practice change)
might be rejected. Ladd (2010) postulated that there is an additional step of reevaluation that is
needed when the innovation is a practice change. This reevaluation step can occur at two
different points in the process. After the initial rejection step and after the confirmation step, if
the innovation is not formally adopted (Figure 5). This step allows for the members to reassess
the practice change and determine if there are any changes that can be made that would make the
practice change more compatible with both the members and the practice in general. The general
concept for this reevaluation step is that it is difficult to assess whether or not a practice change
concept will work until it is introduced into the systems. In addition, if the members know that
they will be able to have continuing input into the practice change, they may be more willing to
adopt it. The practice change using the lipid tracking form was not formally adopted by the
practice. However, the concept was generally well received and while the form in its current
state was not adopted, a modified version the form is being developed that will track other
chronic diseases as well. Specific aspects regarding the lack of adoption of the practice change
were reviewed in the context of Rogers Theory.
Adopter categories.
The theory identifies five adopter categories: (1) innovators; (2) early adopters; (3) the
early majority; (4) the late majority; and (5) laggards. The distribution of the adopter categories
usually follows a normal distribution (Figure 6). It can be difficult in a small practice have
sufficient numbers for this distribution. Even with intimate knowledge of the system, it is
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difficult to determine into which categories people fall. The innovator for this practice change
was the project leader. Provider One was an early adopter, and was involved in the process.
Provider Two acted in the manner of a member of the early majority category however, after the
evaluation phase, it was discovered that Provider Two was actually a laggard. The system
(practice) into which this innovation was introduced did not have the usual distribution in the
adopter categories. This is most likely due the small number of providers involved. Other
members of the ancillary staff who were in the late majority category did not significantly affect
the distribution. In order to assess the congruence of the theory with the practice change, the
distribution of the people in each category needs to be assessed at the reevaluation stage to
determine if there is sufficient distribution of the adopters in the system for the practice change
to be successful in the future.
Factors that affect the rate of adoption.
In addition, Rogers describes specific factors that affect the rate of adoption. These
include: (1) the relative advantage; (2) compatibility within the existing system; (3) complexity;
(4) trialability; and (5) observability. In regards to this specific practice change there was a lack
of perceived relative advantage. It is difficult to overcome this without insinuating that there is a
lack in current practice. The proposed practice change did not possess sufficient compatibility
with the current process in the practice. Although it did have compatibility with other practices
in the area, with which the staff was familiar. The practice change was not complex and for the
evaluation phase of the implementation the majority of the work that would become the
responsibility of the ancillary staff was carried out by the project leader. However, were the
practice change to have been formally adopted, the ancillary staff would have been required to
complete those tasks (inputting the most recent lab values in the form). It may be that they
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perceived that as complex. The reevaluation step (Ladd, 2010) addresses the issue of trialability
and was stressed during the process to encourage staff to be more willing to accept the practice
change. In addition, the reevaluation step can also demonstrate the relative advantage of the
practice change. Because the long term effects of adherence to lipid guidelines are not
immediately measurable, there may be a lack of observability. However, there are some aspects
of this practice change, such as trends in lipid values, medication changes and adherence to
follow-up, that would be documented on the form, that are more observable.
Diffusion of Innovations: Stages.
This practice change progressed through the stages described by Rogers (1962) and Ladd
(2010). It was assumed that the providers (both with many years of experience) had a basic
knowledge of the treatment of lipid disorders. That notwithstanding, they were each also
provided with copies of the current guidelines. This was the stage of knowledge attainment. The
second stage, the persuasion stage, was addressed by involving the providers in the process.
Feedback on the lipid-tracking form was obtained and implemented in the final format of the
form. In addition, the development of a basic policy for routine follow-up was developed to be
incorporated on the form. During this stage, both providers demonstrated involvement in the
proposed practice change.
The third stage, the decision making process, involved multiple conversations with the
providers and staff regarding how the process would proceed. Specific details such as where the
form would be placing in the chart were addressed. Once it was decided that the practice would
proceed with the innovation, a timeline was developed. In addition, responsibilities for specific
aspects of the practice change were determined. During that stage, it was clear who the
innovator, early adopter and early majority participants were. During this stage, it was not
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obvious to the project leader that there were a significant number of non-adopters. Had that been
the case the practice change would have needed to be reevaluated.
The fourth stage, the implementation stage, involved the use of the lipid-tracking forms.
The implementation began as planned. However, after the first week of the use of the lipidtracking forms, it became apparent that Provider Two was not participating in the practice
change at all and that Provider One was not completing as many forms as anticipated. It was
unclear to the project leader why this was happening based upon previous indications of support.
Therefore, additional conversations occurred with both providers to determine the issue. During
these conversations both providers verbalized support for the practice change, and support for the
use of the forms. In addition, the instructions for the use of the form (Appendix A) as well as the
ATP-III guideline and Framingham risk scores were provided again to the providers. Despite
this, Provider Two still did not complete any of the forms. Although Provider One did improve
in the number of forms completed, it was still less than what had been anticipated.
The confirmation stage, stage five, is the confirmation stage when the practice is formally
adopted. Because of the distinct difference between the providers regarding the use of the form,
especially with Provider Two failing to complete any forms, the practice change was not
formally adopted. The future of this practice change is technically in the reevaluation stage.
However, based on the current practice dynamics, it will not be adopted practice wide. It is
suspected by this researcher that one of the biggest obstacles to the implementation of this
practice change is the lack of perceived advantage to the current system. It is also suspected that
the lack of perceived advantage (over current practice) will be a significant roadblock in the
implementation of any new practice change regardless of the system.
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Even with intimate knowledge of the practice setting it is difficult to anticipate how
people will behave when faced with change. Even though it was expected that there may have
been some resistance to the practice change, and it was believed that those issues had been
addressed, the actual outcomes were not anticipated. While the project leader did not expect
100% participation, it was certainly not anticipated that one of the providers would completely
dismiss the practice change and be a laggard. There are several lessons that can be learned from
this. The perception of relative advantage on the new practice is crucial to any practice change.
The behaviors of participants prior to implementation, while indicative of future behaviors,
cannot always be predicted or relied on. The culture of the system (practice) is significant. If the
practice has a culture that has been resistant to change, or has not shown evidence of change, the
probability that any new practice will be implemented is small, regardless of assurances to the
contrary. Words are only as good as the actions that follow.
Discussion
There is a large body of evidence that has demonstrated that appropriate lipid
management reduces cardiovascular morbidity and mortality. In addition, it has been
demonstrated that there is a distinct lack of adherence to lipid lowering guidelines for the
management of lipid disorders. There is evidence that the use of a paper based intervention
could modify behavior. The purpose of this capstone project was to evaluate the use of a paper
lipid tracking tool in a primary care setting to determine if it would improve provider adherence
to lipid guidelines. One of the key project objectives was to demonstrate that the lipid tracking
form increased the number of patient who had documented LDL goals. Determination of a
diagnosis of hyperlipidemia is relative to the goal that is determined by the provider. If there is
no documented goal or adequate documentation of cardiovascular risk, the patient may be
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undertreated. LDL goals are not static but are changing targets that need to be reevaluated
frequently. One of the criticisms of ATP-III is that it is too complicated (Sager, et al., 2010) and
leads to too much variation in goals, especially in those at moderate risk.
Limitations of the project.
This project had several limitations. One limitation was the use of a small practice. The
small practice had only two providers (other than the project leader) who were available to
utilize the practice change. Since there were only two providers, it became an issue when one
provider (Provider Two) failed to participate in the project. This left only one provider to
contribute to the evaluation of the practice change. Another limitation of the project was the
length of the evaluation period. In order to better evaluate the improvement in the patients‟ lipid
values, a longer study of six months to one year would be needed. In addition, there would need
to be better use of the intervention.
Project findings.
Even with the limitations, there were some positive findings. Analyses of the baseline
sample showed that there was already good adherence to some of the measures. There was
adherence demonstrated in screening for lipid disorders and documentation of a diagnosis of
hyperlipidemia. The evaluation of the use of medications was not able to be done because of
individual provider preferences and lack of documentation of rationale. Two measures were
compared using the baseline sample and the post practice change samples. These were the
documentation of an LDL goal and appropriate follow-up for lipid disorders. This capstone
project did demonstrate that there was a statistically significant improvement in the number of
patients with documented LDL goals (p=0.000). While there was an increase in the number of
patients who had proper follow-up for lipid disorders, it was not statistically significant
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(p=0.457). The project timeline did not allow for the project leader to assess whether or not
there was an increase in the number of patients who were at or below goal.
Implications
One of the benefits of the lipid tracking form is that it compiles all of the pertinent
information in one place. There is no need to search through a chart or remember a rationale.
This project did demonstrate that the use of a simple paper lipid tracking from did improve
provider adherence to lipid guidelines, but in only one of the four measures. However that
measure, documentation of LDL goals, is a critical step in treating hyperlipidemia. It is
anticipated that the new guidelines (ATP-IV), due to be released in the fall of 2012, will lower
the current goals for primary prevention (Allison, 2010). It will be to provider‟s and patient‟s
benefit to develop tools to help improve provider adherence. If this simple lipid tracking tool
showed improvement even with only one provider participating, it is anticipated that
improvement would also be achieved in other practices in which the providers where willing to
utilize the forms. In addition, the format could be adapted for use in electronic medical record
system so that the information that is important to the management of hyperlipidemia such as,
medication, labs, medication changes, and recommended follow-up could be displayed in one
screen. This project lays the groundwork for future study.
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Figure 1: Average annual age-adjusted rate (deaths per 100,000) for people ages 35 years and
older (CDC, 2009).

Figure 2: Prevalence of elevated cholesterol and indices of increased cardiovascular risk broken
down by gender and race (AHA, 2010).
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Figure 3: Rogers‟ Diffusion of Innovation (Rogers, 1962)
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Figure 4: Ladd‟s (2010) adaption of Rogers‟ Diffusion of Innovation for use in implementing
practice change.
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Figure 5: Ladd‟s further adaption of Rogers‟ Diffusion of Innovation for use in implementing
practice change.
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Figure 6: Diffusion of Innovation s-curve and normal distribution of adopter categories (Rogers,
1962)

IMPROVING PROVIDER ADHERENCE TO LIPID GUIDELINES

44

Appendix A: Instructions for the Lipid Tracking Form

The form will be placed on the charts of patients (except derm visits and joint injection visits)
coming into the office for the next few weeks.
I will be placing the form on the charts after they are prepped and before you see them. I will fill
in the basic data (age and gender) and assign a study ID number.
In addition, I will fill in the labs values from the most recent set of labs that are available to me
when the chart has been prepped.
When you see the patient, please fill in on the form at the time of the visit the following:
1) Identify and check off the patients comorbidities
2) Determine and document (on the form) the patients LDL goal
3) List the patients current medications (OTC too), indicate none if on no lipid-lowering
therapy
4) Note any comments regarding current medication or change in medication (e.g. missed
doses, non compliant, increase to Zocor 40, change to Crestor 5 etc.)
5) Document planned follow-up for lipids (e.g. labs 6 weeks, labs 6 months, etc.)

Thanks
Diane
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